<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(13)</volume><submitter>AlZaabi A</submitter><pubmed_abstract>Here, we assess how the differential expression of low molecular weight serum peptides might predict breast cancer progression with high confidence. We apply an LC/MS-MS-based, unbiased 'omics' analysis of serum samples from breast cancer patients to identify molecules that are differentially expressed in stage I and III breast cancer. Results were generated using standard and machine learning-based analytical workflows. With standard workflow, a discovery study yielded 65 circulating biomarker candidates with statistically significant differential expression. A second study confirmed the differential expression of a subset of these markers. Models based on combinations of multiple biomarkers were generated using an exploratory algorithm designed to generate greater diagnostic power and ac</pubmed_abstract><journal>Cancers</journal><pagination>2365</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11240466</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Differential Serum Peptidomics Reveal Multi-Marker Models That Predict Breast Cancer Progression.</pubmed_title><pmcid>PMC11240466</pmcid><pubmed_authors>Piccolo S</pubmed_authors><pubmed_authors>AlZaabi A</pubmed_authors><pubmed_authors>Hansen M</pubmed_authors><pubmed_authors>Graves S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Differential Serum Peptidomics Reveal Multi-Marker Models That Predict Breast Cancer Progression.</name><description>Here, we assess how the differential expression of low molecular weight serum peptides might predict breast cancer progression with high confidence. We apply an LC/MS-MS-based, unbiased 'omics' analysis of serum samples from breast cancer patients to identify molecules that are differentially expressed in stage I and III breast cancer. Results were generated using standard and machine learning-based analytical workflows. With standard workflow, a discovery study yielded 65 circulating biomarker candidates with statistically significant differential expression. A second study confirmed the differential expression of a subset of these markers. Models based on combinations of multiple biomarkers were generated using an exploratory algorithm designed to generate greater diagnostic power and ac</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jun</publication><modification>2026-05-28T03:07:56.436Z</modification><creation>2026-05-28T03:06:26.82Z</creation></dates><accession>S-EPMC11240466</accession><cross_references><pubmed>39001426</pubmed><doi>10.3390/cancers16132365</doi></cross_references></HashMap>